Steris plc stock (IE00BFY8C754): shares trade near USD 212 after FY 2026 10-K filing

Steris plc shares in the United States traded close to the low-USD-210 range on the New York Stock Exchange after the company filed its fiscal 2026 Form 10-K and reiterated full-year figures of USD 5.94 billion in revenue and diluted earnings per share of USD 7.93 for the period ended 03/31/2026, according to Steris investor information as of 05/29/2026 and a 10-K summary published on 05/29/2026.

The healthcare equipment group, which is headquartered in the United States and listed on the NYSE under the ticker STE, reported net income attributable to shareholders of about USD 782.3 million for fiscal 2026 and remains positioned as a leading global supplier of sterilization and infection prevention solutions, according to a 10-K overview dated 05/29/2026 on TradingView as of 05/29/2026.

The stock traded at about USD 212.50 on 05/29/2026 on the NYSE, implying a modest pullback of roughly 1.3 percent on the day, according to end-of-day data from MarketBeat as of 05/29/2026.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Steris plc: core business model

Operating as a specialist in infection prevention, Steris focuses on supplying sterilization equipment, related services and consumable products whose adoption in hospitals, life sciences manufacturing and medical device processing drives the bulk of its revenue.

Insider activity and ownership structure

Recent filings indicate that insiders and key executives at Steris have continued to hold significant equity exposure while operating against a backdrop of steady earnings, although there have been no large, market-moving director dealing disclosures reported by major US newswires in the last few weeks, and institutional analysts still highlight the company primarily for its stable cash generation and healthcare exposure rather than for any sudden changes in insider positioning.

On the ownership side, Steris remains widely held by institutional investors in the United States, with asset managers and pension funds occupying a large share of the register, and the company’s 10-K emphasizes a long-term orientation toward reinvestment and bolt-on acquisitions to support growth in its core sterilization and infection prevention activities, according to a SWOT-style review of the filing published on 05/29/2026 by GuruFocus as of 05/29/2026.

Conclusion

With fiscal 2026 results now fully detailed in its 10-K, Steris offers investors updated visibility on revenue of USD 5.94 billion, diluted EPS of USD 7.93 and net income of about USD 782.3 million, all against the backdrop of a share price near USD 212 on the NYSE.

The insider and ownership picture remains characterized by broad institutional holdings rather than large, disruptive director dealings, leaving the market to focus on the company’s core strengths in sterilization, infection prevention and healthcare infrastructure demand when assessing the stock’s medium-term risk-reward profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.